Irritable Bowel Syndrome Stocks List

Irritable Bowel Syndrome Stocks Recent News

Date Stock Title
Nov 20 LXRX Lexicon Appoints Ivan H. Cheung to Board of Directors
Nov 20 ABBV Unpacking the Latest Options Trading Trends in AbbVie
Nov 20 ABT Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Nov 20 ARDX Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
Nov 19 ARDX High Growth Tech Stocks To Explore In November 2024
Nov 19 ABBV Where Will AbbVie Be in 5 Years?
Nov 19 ABBV ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
Nov 19 ABBV RVPH: Year-End OLE Update
Nov 19 ABBV What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
Nov 18 ABBV AbbVie snaps eight straight sessions of losses
Nov 18 ABBV Aldeyra announces FDA acceptance of resubmitted reproxalap application
Nov 18 ABBV AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
Nov 18 ABT Inside a $400 billion bet on the brain-computer interface revolution
Nov 18 BHC US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
Nov 18 ABBV Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov 18 ARDX US Penny Stocks To Monitor In November 2024
Nov 18 LXRX Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week
Nov 18 BHC Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Nov 18 BHC PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
Nov 18 ABBV AbbVie’s Elahere wins European approval for certain ovarian cancers
Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a group of symptoms—including abdominal pain and changes in the pattern of bowel movements without any evidence of underlying damage. These symptoms occur over a long time, often years. It has been classified into four main types depending on whether diarrhea is common, constipation is common, both are common, or neither occurs very often (IBS-D, IBS-C, IBS-M, or IBS-U respectively). IBS negatively affects quality of life and may result in missed school or work. Disorders such as anxiety, major depression, and chronic fatigue syndrome are common among people with IBS.The causes of IBS are not clear. Theories include combinations of gut–brain axis problems, gut motility disorders, pain sensitivity, infections including small intestinal bacterial overgrowth, neurotransmitters, genetic factors, and food sensitivity. Onset may be triggered by an intestinal infection, or stressful life event. IBS is a functional gastrointestinal disorder. Diagnosis is based on signs and symptoms in the absence of worrisome features. Worrisome features include onset at greater than 50 years of age, weight loss, blood in the stool, or a family history of inflammatory bowel disease. Other conditions that may present similarly include celiac disease, microscopic colitis, inflammatory bowel disease, bile acid malabsorption, and colon cancer.There is no known cure for IBS. Treatment is carried out to improve symptoms. This may include dietary changes, medication, probiotics, and counseling. Dietary measures include increasing soluble fiber intake, a gluten-free diet, or a short-term diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs). The medication loperamide may be used to help with diarrhea while laxatives may be used to help with constipation. Antidepressants may improve overall symptoms and pain. Patient education and a good doctor–patient relationship are an important part of care.About 10 to 15% of people in the developed world are believed to be affected by IBS. It is more common in South America and less common in Southeast Asia. It is twice as common in women as men and typically occurs before age 45. The condition appears to become less common with age. IBS does not affect life expectancy or lead to other serious diseases. The first description of the condition was in 1820 while the current term "irritable bowel syndrome" came into use in 1944.

Browse All Tags